<p num="36">FIELD: biotechnology.</p> <p num="37">SUBSTANCE: invention relates to biotechnology, specifically to recombinant production of therapeutic proteins, and can be used to produce a tumor necrosis factor antagonist. Using genetic engineering methods, a tumor necrosis factor fusion polypeptide antagonist is obtained, consisting of a soluble extracellular domain of human TNFR1 and a constant portion of the heavy chain of human IgG4.</p> <p num="38">EFFECT: invention provides producing a TNFR1-Fc fusion protein which has potentially improved pharmacokinetic properties and a minimal effector function of antibody-dependent cell cytotoxicity, but is not characterized by complement-dependent cytotoxicity, due to the introduction of a hinge section allowing the ectodomain TNFR1 and the Fc domain to act independently.</p> <p num="39">4 cl, 1 dwg, 2 ex</p>